fluorouracil has been researched along with Allergy, Drug in 56 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Furthermore, the delayed hypersensitivity response (DHR) against picryl chloride (PCl) was augmented by FD-1 but not by FT and FU if they were administrated for 3 days after PCl immunization." | 7.66 | Differential effects of 5-fluorouracil analogs on humoral and cell-mediated responses in mice: augmentation of delayed hypersensitivity response against picryl chloride by 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1), a new anti-tumor ( Miyauchi, S; Unemi, N; Yamada, Y, 1980) |
| "This study was designed to determine if histopathologic evaluation of patients with resectable colorectal cancer following preoperative chemotherapy with uracil and tegafur with a molar ratio of 4:1 (UFT) could predict chemosensitivity to postoperative fluoropyrimidines to prevent recurrence of disease." | 5.09 | Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer. ( Fujii, M, 1999) |
| "Data on patients with colorectal cancer who received FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) treatment between June 2005 and June 2009 were retrieved from the prospective cohort database of the Outpatient Oncology Unit of the Kyoto University Hospital." | 3.76 | Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. ( Chiba, T; Fukushima, M; Hazama, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Mori, Y; Nagayama, S; Nishimura, T; Sakai, Y; Teramukai, S; Yanagihara, K; Yoshimura, K, 2010) |
| "Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC." | 3.75 | Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. ( Akashi, K; Ariyama, H; Baba, E; Esaki, T; Kusaba, H; Mitsugi, K; Nakano, S; Shibata, Y; Takii, Y; Tsuchiya, T, 2009) |
| "To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine." | 3.71 | Fluorouracil for allergic reactions to capecitabine. ( Liu, CY, 2002) |
| "Although treatment with 5-fluorouracil (5-FU) plus calcium folinate has been reported to prolong survival in patients with metastatic colorectal cancer, it can also cause significant toxicity, potentially, resulting in hospitalization." | 3.70 | Hospitalization for 5-FU toxicity in metastatic colorectal cancer: incidence and cost. ( Oster, G, 1999) |
| "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function." | 3.67 | Allergic reaction to 5-fluorouracil infusion. ( Sridhar, KS, 1986) |
| " Furthermore, the delayed hypersensitivity response (DHR) against picryl chloride (PCl) was augmented by FD-1 but not by FT and FU if they were administrated for 3 days after PCl immunization." | 3.66 | Differential effects of 5-fluorouracil analogs on humoral and cell-mediated responses in mice: augmentation of delayed hypersensitivity response against picryl chloride by 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1), a new anti-tumor ( Miyauchi, S; Unemi, N; Yamada, Y, 1980) |
| "The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin (OXA) in combination with continuous infusional 5-fluorouracil (5-FU) and leucovorin (LV) administered every 2 weeks (modified FOLFOX-4 regimen) in elderly patients with advanced gastric cancer (AGC)." | 2.73 | Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. ( Fu, Z; Guan, F; Guo, QS; Liu, ZF; Wang, MY; Yang, XG; Zhang, XQ, 2008) |
| "Colorectal cancer is one of the most common cancers affecting men and women in the United States." | 2.43 | Advanced colorectal cancer: current treatment and nursing management with economic considerations. ( Fung, A; Viale, PH; Zitella, L, 2005) |
| " Potential correlation between treatment modalities (regimen, dosage and route of administration of L-OHP, and injection timing for dexamethasone administration) and HSRs was assessed." | 1.46 | Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer. ( Ando, Y; Hayashi, T; Ikeda, Y; Ito, K; Kawada, K; Kumazawa, S; Maeda, K; Matsuoka, H; Murai, S; Ohta, H; Shiouchi, H; Yamada, S; Yasuda, K, 2017) |
| " This infusion rate is safe for use in routine practice." | 1.43 | Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min. ( Cercek, A; Kemeny, NE; Park, V; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Stadler, ZK; Varghese, A; Yaeger, R, 2016) |
| " Another option is to use desensitization protocols that induce a temporary state of tolerance by gradually administering small quantities of the antineoplastic drug until the therapeutic dosage is reached." | 1.39 | Effectiveness of oxaliplatin desensitization protocols. ( Aguilella-Vizcaíno, MJ; Calleja-Hernández, MÁ; Cortés-Funes Castro, H; Cortijo-Cascajares, S; García-Escobar, I; Herreros-de-Tejada, A; Nacle-López, I, 2013) |
| "We retrospectively investigated the frequency and severity of adverse events in 124 patients with colorectal cancer who were treated by mFOLFOX6 regimen from August, 2005 to December, 2006." | 1.35 | [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen]. ( Boku, N; Kato, T; Kimura, H; Kudou, Y; Matsunaga, Y; Motokawa, S; Muramatsu, T; Nagata, N; Nakagaki, S; Ohashi, Y; Shino, M; Yamazaki, K; Yoshida, T, 2009) |
| "Anaphylactic shock, is rare but serious, and must be considered in the event of any severe blood pressure decrease." | 1.33 | Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. ( André, T; De Gramont, A; Louvet, C; Maindrault-Goebel, F; Perez-Staub, N; Tournigand, C; Zeghib, N, 2005) |
| "We report a patient with metastatic colon cancer who developed a hypersensitivity reaction to oxaliplatin during the sixth cycle of combination chemotherapy with oxaliplatin, high-dose 5-fluorouracil and leucovorin." | 1.32 | Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. ( Chang, MC; Chang, YF; Hsieh, RK; Huang, MJ; Lim, KH; Lin, HC; Lin, J; Su, YW, 2004) |
| "Fluorouracil-induced pneumonitis was subsequently diagnosed." | 1.30 | [A case of fluorouracil-induced pneumonitis]. ( Andou, H; Itoh, K; Tsuda, T, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (25.00) | 18.7374 |
| 1990's | 6 (10.71) | 18.2507 |
| 2000's | 18 (32.14) | 29.6817 |
| 2010's | 18 (32.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsumoto, H | 1 |
| Ishihara, Y | 1 |
| Masumoto, S | 1 |
| Kawamoto, K | 1 |
| Takayanagi, K | 1 |
| Ohta, H | 1 |
| Hayashi, T | 1 |
| Murai, S | 1 |
| Shiouchi, H | 1 |
| Ando, Y | 1 |
| Kumazawa, S | 1 |
| Ito, K | 1 |
| Ikeda, Y | 1 |
| Matsuoka, H | 1 |
| Maeda, K | 1 |
| Kawada, K | 1 |
| Yasuda, K | 1 |
| Yamada, S | 1 |
| Kounis, NG | 1 |
| Koniari, I | 1 |
| Patsouras, N | 1 |
| Koutsogiannis, N | 1 |
| Velissaris, D | 1 |
| Soufras, G | 1 |
| Hahalis, G | 1 |
| Maughan, C | 1 |
| Lear, W | 1 |
| Ureña-Tavera, A | 1 |
| Zamora-Verduga, M | 1 |
| Madrigal-Burgaleta, R | 1 |
| Angel-Pereira, D | 1 |
| Berges-Gimeno, MP | 1 |
| Alvarez-Cuesta, E | 1 |
| Florit-Sureda, M | 1 |
| Conde-Estévez, D | 1 |
| Vidal, J | 1 |
| Montagut, C | 1 |
| Suenaga, M | 1 |
| Mizunuma, N | 1 |
| Matsusaka, S | 1 |
| Shinozaki, E | 1 |
| Ozaka, M | 1 |
| Ogura, M | 1 |
| Yamaguchi, T | 1 |
| Cercek, A | 1 |
| Park, V | 1 |
| Yaeger, R | 1 |
| Reidy-Lagunes, D | 1 |
| Kemeny, NE | 1 |
| Stadler, ZK | 1 |
| Segal, NH | 1 |
| Varghese, A | 1 |
| Saltz, LB | 1 |
| Danesi, R | 1 |
| Del Re, M | 1 |
| Ciccolini, J | 1 |
| Schellens, JHM | 1 |
| Schwab, M | 1 |
| van Schaik, RHN | 1 |
| van Kuilenburg, ABP | 1 |
| Liu, ZF | 1 |
| Guo, QS | 1 |
| Zhang, XQ | 1 |
| Yang, XG | 1 |
| Guan, F | 1 |
| Fu, Z | 1 |
| Wang, MY | 1 |
| Nozawa, H | 1 |
| Muto, Y | 1 |
| Yamada, Y | 3 |
| Ichikawa, Y | 1 |
| Goto, A | 1 |
| Hirokawa, S | 1 |
| Kijima, M | 1 |
| Ishikawa, T | 1 |
| Chishima, T | 1 |
| Suwa, H | 1 |
| Yamamoto, H | 1 |
| Yamagishi, S | 1 |
| Osada, S | 1 |
| Ota, M | 1 |
| Fujii, S | 1 |
| Kato, T | 1 |
| Matsunaga, Y | 1 |
| Motokawa, S | 1 |
| Nakagaki, S | 1 |
| Nagata, N | 1 |
| Yoshida, T | 1 |
| Muramatsu, T | 1 |
| Kimura, H | 1 |
| Ohashi, Y | 1 |
| Kudou, Y | 1 |
| Shino, M | 1 |
| Yamazaki, K | 1 |
| Boku, N | 1 |
| Shibata, Y | 1 |
| Ariyama, H | 1 |
| Baba, E | 1 |
| Takii, Y | 1 |
| Esaki, T | 1 |
| Mitsugi, K | 1 |
| Tsuchiya, T | 1 |
| Kusaba, H | 1 |
| Akashi, K | 1 |
| Nakano, S | 1 |
| Okada, N | 1 |
| Ishibashi, K | 1 |
| Kuwabara, K | 1 |
| Ishiguro, T | 1 |
| Hatano, S | 1 |
| Hokama, N | 1 |
| Tajima, Y | 1 |
| Ishii, M | 1 |
| Kubota, S | 1 |
| Chika, N | 1 |
| Miyazaki, T | 1 |
| Ishida, H | 1 |
| Zhao, Y | 1 |
| An, X | 1 |
| Xiang, XJ | 1 |
| Feng, F | 1 |
| Wang, FH | 1 |
| Wang, ZQ | 1 |
| Xu, RH | 1 |
| He, YJ | 1 |
| Li, YH | 1 |
| Yürek, S | 1 |
| Riess, H | 1 |
| Kreher, S | 1 |
| Dörken, B | 1 |
| Salama, A | 1 |
| Mori, Y | 1 |
| Nishimura, T | 1 |
| Kitano, T | 1 |
| Yoshimura, K | 1 |
| Matsumoto, S | 1 |
| Kanai, M | 1 |
| Hazama, M | 1 |
| Ishiguro, H | 1 |
| Nagayama, S | 1 |
| Yanagihara, K | 1 |
| Teramukai, S | 1 |
| Chiba, T | 1 |
| Sakai, Y | 1 |
| Fukushima, M | 1 |
| Kidera, Y | 1 |
| Satoh, T | 1 |
| Ueda, S | 1 |
| Okamoto, W | 1 |
| Okamoto, I | 1 |
| Fumita, S | 1 |
| Yonesaka, K | 1 |
| Hayashi, H | 1 |
| Makimura, C | 1 |
| Okamoto, K | 1 |
| Kiyota, H | 1 |
| Tsurutani, J | 1 |
| Miyazaki, M | 1 |
| Yoshinaga, M | 1 |
| Fujiwara, K | 1 |
| Yamazoe, Y | 1 |
| Moriyama, K | 1 |
| Tsubaki, M | 1 |
| Chiba, Y | 1 |
| Nishida, S | 1 |
| Nakagawa, K | 1 |
| Damaske, A | 1 |
| Ma, N | 1 |
| Williams, R | 1 |
| Seki, K | 1 |
| Senzaki, K | 1 |
| Tsuduki, Y | 1 |
| Ioroi, T | 1 |
| Fujii, M | 2 |
| Yamauchi, H | 1 |
| Shiraishi, Y | 1 |
| Nakata, I | 1 |
| Nishiguchi, K | 1 |
| Matsubayashi, T | 1 |
| Takakubo, Y | 1 |
| Okamura, N | 1 |
| Yamamori, M | 1 |
| Tamura, T | 1 |
| Sakaeda, T | 1 |
| Yanai, T | 1 |
| Iwasa, S | 1 |
| Kim, MY | 1 |
| Kang, SY | 1 |
| Lee, SY | 1 |
| Yang, MS | 1 |
| Kim, MH | 1 |
| Song, WJ | 1 |
| Kim, SH | 1 |
| Kim, YJ | 1 |
| Lee, KW | 1 |
| Cho, SH | 1 |
| Min, KU | 1 |
| Lee, JS | 1 |
| Kim, JH | 1 |
| Chang, YS | 1 |
| Cortijo-Cascajares, S | 1 |
| Nacle-López, I | 1 |
| García-Escobar, I | 1 |
| Aguilella-Vizcaíno, MJ | 1 |
| Herreros-de-Tejada, A | 1 |
| Cortés-Funes Castro, H | 1 |
| Calleja-Hernández, MÁ | 1 |
| Kempin, S | 1 |
| Gutierrez, J | 1 |
| Wilson, E | 1 |
| Lowery, C | 1 |
| Diasio, R | 1 |
| Liu, CY | 1 |
| Garufi, C | 1 |
| Cristaudo, A | 1 |
| Vanni, B | 1 |
| Bria, E | 1 |
| Aschelter, AM | 1 |
| Santucci, B | 1 |
| Terzoli, E | 1 |
| Tsokos, GC | 1 |
| Lim, KH | 1 |
| Huang, MJ | 1 |
| Lin, HC | 1 |
| Su, YW | 1 |
| Chang, YF | 1 |
| Lin, J | 1 |
| Chang, MC | 1 |
| Hsieh, RK | 1 |
| Ng, CV | 1 |
| Brennan, DD | 1 |
| Farrelly, C | 1 |
| Cooney, R | 1 |
| Norris, S | 1 |
| McEniff, N | 1 |
| Maindrault-Goebel, F | 1 |
| André, T | 1 |
| Tournigand, C | 1 |
| Louvet, C | 1 |
| Perez-Staub, N | 1 |
| Zeghib, N | 1 |
| De Gramont, A | 1 |
| Viale, PH | 1 |
| Fung, A | 1 |
| Zitella, L | 1 |
| Noronha, V | 1 |
| Burtness, B | 1 |
| Murren, J | 1 |
| Duffy, TP | 1 |
| Lemperle, G | 1 |
| Rullan, PP | 1 |
| Gauthier-Hazan, N | 1 |
| Wrzesinski, SH | 1 |
| McGurk, ML | 1 |
| Donovan, CT | 1 |
| Ferencz, TM | 1 |
| Saif, MW | 1 |
| Spencer, HJ | 1 |
| Miyauchi, S | 1 |
| Unemi, N | 1 |
| Hashimi, LA | 1 |
| Khalyl, MF | 1 |
| Salem, PA | 1 |
| Epstein, E | 1 |
| Andou, H | 1 |
| Itoh, K | 1 |
| Tsuda, T | 1 |
| Duley, JA | 1 |
| Nethersell, AB | 1 |
| Oster, G | 1 |
| Bernstein, T | 1 |
| Omura, EF | 1 |
| Biran, S | 1 |
| krasnokuki, D | 1 |
| Brufman, G | 1 |
| Weiss, RB | 1 |
| Falliers, CJ | 1 |
| Sridhar, KS | 1 |
| Sevadjian, CM | 1 |
| Klein, E | 1 |
| Sirotnak, FM | 1 |
| Kurita, S | 1 |
| Sargent, MG | 1 |
| Robinson, DL | 1 |
| Hutchison, DJ | 2 |
| Lewis, RJ | 1 |
| Bendl, BJ | 1 |
| Awe, WC | 1 |
| Donaldson, SS | 1 |
| Fletcher, WS | 1 |
| Hoshino, A | 1 |
| Albrecht, AM | 1 |
7 reviews available for fluorouracil and Allergy, Drug
| Article | Year |
|---|---|
Hypersensitivity reaction caused by folinic acid administration: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Hypersensitivity; Fluorourac | 2016 |
[FOLFOX-related hypersensitivity reactions: clinical presentation and management].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Hypersensitivity; Fluorou | 2011 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2005 |
Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature.
Topics: Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2005 |
Avoiding and treating dermal filler complications.
Topics: Adipose Tissue; Adrenal Cortex Hormones; Animals; Autoimmune Diseases; Biocompatible Materials; Catt | 2006 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomyc | 1992 |
Local cytostatic chemotherapy and immunotherapy.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Drug Hypersensitivity; Fluorouracil; Humans; Neoplasms | 1968 |
4 trials available for fluorouracil and Allergy, Drug
| Article | Year |
|---|---|
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2015 |
Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2008 |
Skin testing and hypersensitivity reactions to oxaliplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Hy | 2003 |
Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1999 |
45 other studies available for fluorouracil and Allergy, Drug
| Article | Year |
|---|---|
[Effectiveness of Allergy Regimen for Allergic Reactions to Oxaliplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Hypersensitivity; Fluorou | 2019 |
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Topics: Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2017 |
Coronary vasospasm associated with 5-fluorouracil chemotherapy: Cardiac toxicity or cardiac hypersensitivity?
Topics: Acute Coronary Syndrome; Cardiotoxicity; Coronary Vasospasm; Drug Hypersensitivity; Fluorouracil; Hu | 2017 |
Acute angioedema response to topical 5-fluorouracil therapy.
Topics: Administration, Topical; Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Antimetabolites | 2013 |
Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Hypersen | 2015 |
Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Administration Schedule; Drug Hyp | 2016 |
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?
Topics: Dihydrouracil Dehydrogenase (NADP); Drug Hypersensitivity; Fluorouracil; Humans; Pyrimidines | 2017 |
Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Desensitization, Immunologic; | 2008 |
Allergic reactions to oxaliplatin in a single institute in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Hypersensitivity; Female; Fluorouracil; H | 2009 |
[Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2009 |
[The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2009 |
[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anaphylaxis; Anti-Allergic Agents | 2010 |
Fatal immune haemolysis due to antibodies to individual metabolites of 5-fluorouracil.
Topics: Anemia; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2010 |
Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2010 |
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Topics: Adenocarcinoma; Anti-Allergic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies | 2011 |
Leucovorin-induced hypersensitivity reaction.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2012 |
Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycy | 2012 |
Effectiveness of oxaliplatin desensitization protocols.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Colonic Diseases; D | 2002 |
Fluorouracil for allergic reactions to capecitabine.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Hypersensitivity; | 2002 |
Drugs, sun and T cells in lupus.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantibodies; Dermatitis, Photoallergic; Drug Hypersens | 2004 |
Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Desen | 2004 |
Hypersensitivity reactions to oxaliplatin in two asian patients.
Topics: Adult; Anti-Allergic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2005 |
Abdominal rash after transarterial chemoembolization via the right inferior phrenic artery.
Topics: Abdomen; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Arteries; Chemoembolization, | 2005 |
Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2005 |
Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Drug Hyper | 2007 |
Local erythema multiforme-like drug reaction following intravenous mitomycin C and 5-fluorouracil.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Small Cell; Drug Hypersensitivity; Erythema Multiforme | 1984 |
Differential effects of 5-fluorouracil analogs on humoral and cell-mediated responses in mice: augmentation of delayed hypersensitivity response against picryl chloride by 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1), a new anti-tumor
Topics: Animals; Antibody Formation; Drug Hypersensitivity; Fluorouracil; Graft Rejection; Hypersensitivity, | 1980 |
Supraventricular tachycardia. A probable complication of platinum treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cystadenocarcinoma; Dox | 1984 |
Testing for 5 fluorouracil allergy: patch and intradermal tests.
Topics: Drug Hypersensitivity; Fluorouracil; Humans; Intradermal Tests; Patch Tests | 1984 |
[A case of fluorouracil-induced pneumonitis].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Hypersensitivity; Fluorouracil; Hu | 1997 |
Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Creatinine; Dihydrouracil Dehydrogenase (NADP | 1998 |
Hospitalization for 5-FU toxicity in metastatic colorectal cancer: incidence and cost.
Topics: Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; Cost of Illness; Drug Hyperse | 1999 |
Skin reactions to 5-fluorouracil.
Topics: Breast Neoplasms; Drug Eruptions; Drug Hypersensitivity; Female; Fluorouracil; Humans; Injections, I | 1977 |
Skin reaction to systemic 5-FU -- a therapeutic bonus.
Topics: Administration, Topical; Drug Hypersensitivity; Fluorouracil; Humans; Injections; Skin | 1977 |
[Life-threatening gastrointestinal toxicity during 5-fluorouracil therapy].
Topics: Diarrhea; Drug Hypersensitivity; Fluorouracil; Humans | 1977 |
Cancer chemotherapy: hormonal changes and recurring asthma.
Topics: Adenocarcinoma; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asthma; Breast Ne | 1991 |
Allergic reaction to 5-fluorouracil infusion.
Topics: Angioedema; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dru | 1986 |
Pustular contact hypersensitivity to fluorouracil with rosacealike sequelae.
Topics: Administration, Topical; Dermatitis, Contact; Drug Hypersensitivity; Facial Dermatoses; Female; Fluo | 1985 |
Sequential biochemical alteration to antifolate resistance in L1210 leukaemia.
Topics: Animals; Biological Transport, Active; Cell Division; Cytogenetics; Drug Hypersensitivity; Fluoroura | 1967 |
Erythroplasia of Queyrat: repor. of a patient successfully treated with topical 5-fluorouracil.
Topics: Adult; Drug Hypersensitivity; Erythroplasia; Fluorouracil; Humans; Male; Penile Diseases; Precancero | 1971 |
Increased sensitivity to 5-fluorouracil in patients with adrenal insufficiency.
Topics: Adrenal Insufficiency; Aged; Drug Hypersensitivity; Female; Fluorouracil; Humans; Middle Aged | 1966 |
Fate of amethopterin-resistant mutants in L1210 mouse leukemia populations.
Topics: Animals; Drug Hypersensitivity; Fluorouracil; In Vitro Techniques; Leukemia L1210; Mercaptopurine; M | 1966 |